Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 870 across all filing types
Latest filing 2023-04-18 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
中审众环会计师事务所(特殊普通合伙)关于圣湘生物科技股份有限公司2022年度非经营性资金占用及其他关联资金往来情况汇总表的专项审核报告
Audit Report / Information Classification · 95% confidence The document is a specialized audit report titled "专项审核报告" related to the summary table of non-operating fund occupation and other related party fund transactions for the year 2022 of 圣湘生物科技股份有限公司. It is issued by a certified public accounting firm and includes detailed financial data and audit opinions. The document contains substantive financial data and audit results, not just an announcement or certification. It is not a full annual report but a standalone audit report focusing on a specific financial aspect, consistent with the definition of an Audit Report / Information (AR). FY 2022
2023-04-18 Chinese
中审众环会计师事务所(特殊普通合伙)关于圣湘生物科技股份有限公司2022年度审计报告
Regulatory Filings
2023-04-18 Chinese
湖南启元律师事务所关于圣湘生物科技股份有限公司2023 年限制性股票激励计划（草案）的法律意见书
Regulatory Filings
2023-04-18 Chinese
圣湘生物科技股份有限公司2023年限制性股票激励计划实施考核管理办法
Governance Information Classification · 95% confidence The document is titled '2023 年限制性股票激励计划实施考核管理办法' which translates to '2023 Restricted Stock Incentive Plan Implementation Assessment Management Measures'. It details the rules, principles, scope, assessment institutions, performance indicators, procedures, and management related to the company's restricted stock incentive plan for 2023-2024. The content focuses on governance and management of an equity incentive plan, including performance evaluation and stock vesting conditions. There is no financial statement, earnings data, or regulatory filing announcement. It is not a report of financial results, audit, or legal proceeding. It is also not a shareholder meeting material or voting result. The document is a governance-related policy document concerning stock incentives and management of executive compensation through equity plans. Therefore, it fits best under Governance Information (CGR), which covers internal rules, board structure, and governance practices including incentive plans and compensation policies.
2023-04-18 Chinese
圣湘生物科技股份有限公司2023年限制性股票激励计划（草案）
Remuneration Information Classification · 95% confidence The document is titled "圣湘生物科技股份有限公司 2023 年限制性股票激励计划（草案）" which translates to "2023 Restricted Stock Incentive Plan (Draft)" for the company 圣湘生物科技股份有限公司. The content extensively details the company's stock incentive plan, including definitions, objectives, management, scope, conditions for granting and vesting restricted stock, performance targets, adjustment methods, and accounting treatment. It is a comprehensive plan document related to equity-based compensation for directors and senior management. This type of document is related to remuneration and compensation information for executives and directors rather than a general management change announcement or a financial report. It is not an announcement of voting results or a proxy solicitation, but a detailed plan document. Therefore, the most appropriate classification is "Remuneration Information (DEF 14A)" which covers reports detailing compensation for top executives and directors, including stock incentive plans.
2023-04-18 Chinese
圣湘生物科技股份有限公司关于2022年度利润分配方案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2022 annual profit distribution plan of the company 圣湘生物科技股份有限公司. It details the dividend per share, total dividend amount, and the approval process by the board and supervisory committee. It does not contain full financial statements or comprehensive financial performance data, but rather focuses on the dividend distribution plan and related corporate governance approvals. This fits the category of Notice of Dividend Amount (DIV), which covers announcements of dividend amounts, payment dates, and details for shareholders.
2023-04-18 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.